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Abstract: Highly active antiretroviral therapy has signiﬁ  cantly reduced HIV-related morbidity 
and mortality. Increasingly, ﬁ  xed-dose antiretroviral combinations with equal or greater potency 
than traditional antiretrovirals, along with fewer side effects, reduced toxicity, and simpliﬁ  ed 
dosing convenience are being utilized. Tenofovir-emtricitabine (TDF-FTC) represents one of the 
more recent ﬁ  xed-dose combinations. In combination with either a ritonavir-boosted protease 
inhibitor or a non-nucleoside reverse transcriptase inhibitor, TDF-FTC is a preferred choice in 
recent treatment guidelines on the basis of demonstrated potency in randomized clinical trials, 
one-pill-a-day dosing convenience, and relatively low toxicity. In addition, the drug is active 
against hepatitis B virus. Caution must be exercised in patients with renal insufﬁ  ciency, or 
when the drug is used with certain other drugs. This manuscript reviews the use of TDF-FTC 
in the treatment of HIV .
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Introduction
Health care practitioners and researchers have been ﬁ  ghting human immunode-
ﬁ  ciency virus (HIV) infection for over two decades. During this time, signiﬁ  cant 
progress has been made in understanding the pathogenesis, clinical presentation, and 
epidemiology of the disease. The advent of antiretroviral therapy has signiﬁ  cantly 
improved the prognosis and quality of life of persons living with HIV . Currently, 
over 20 antiretroviral drugs have been approved by the Food and Drug Administration 
(FDA) for the treatment of HIV infection. These agents are classiﬁ  ed into: (a) nucleo-
side/nucleotide reverse transcriptase inhibitors (NRTI/NtRTI), (b) non-nucleoside 
reverse transcriptase inhibitors (NNRTI), (c) protease inhibitors (PI), and (d) fusion 
inhibitors. Despite the increased number of choices, issues of adherence, tolerability, 
long-term toxicity, and drug resistance remain to be some of the major challenges in 
the management of HIV. To address these problems, advances have been made in the 
development of novel agents and ﬁ  xed-dose combination treatment regimens with 
greater potency, lower toxicity, and improved convenience for patients.
Central among the factors affecting adherence and compliance in the treatment 
of HIV/AIDS are antiretroviral dosing frequency and pill burden. The effort toward 
reduced dosing frequency and pill burden has led to the ﬁ  rst FDA-approved, once a 
day, single pill treatment for HIV that contains three antiretroviral medications – efa-
virenz, tenofovir, and emtricitabine. However, many patients must continue to take 
more complicated and toxic HIV therapeutic regimens due to drug intolerance or drug 
resistance (Masquelier et al 2005; Ross et al 2007). Tenofovir disoproxil fumarate-
emtricitabine (TDF-FTC) is a once-daily, ﬁ  xed-dose NtRTI/NRTI combination that 
has demonstrated efﬁ  cacy in well-designed clinical trials with good follow up (Pozniak 
et al 2005; Gallant et al 2006; Pozniak et al 2006). TDF-FTC combines the beneﬁ  ts 
of less toxicity, dosing simplicity, and favorable pharmacokinetic properties (Table 
1). This article will review the current use of this versatile NtRTI/NRTI combination 
in the management of HIV patients.Therapeutics and Clinical Risk Management 2007:3(6) 1098
Masho et al
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To better understand the characteristics of TDF-FTC, 
it is essential to examine its components, TDF and FTC 
(Table 2).
Tenofovir disoproxil fumarate (TDF, 
Viread®)
Approved by the FDA in 2001, TDF (the ester prodrug of 
tenofovir) is hydrolyzed to tenofovir intracellularly and phos-
phorylated to the active metabolite, tenofovir diphosphate 
(Lyseng-Williamson et al 2005). Tenofovir is a nucleotide 
analog of deoxyadenosine monophosphate, with activity 
against HIV-1, -2 and Hepatitis B virus (HBV) (Mulato and 
Cherrington 1997; Robbins et al 1998). Because of its long 
half-life (17 hours), it is administered once daily with other 
antiretroviral drugs. Several clinical trials indicated that TDF is 
highly potent in both treatment-naïve and experienced patients 
at reducing HIV viral load signiﬁ  cantly (Squires et al 2003; 
Gallant et al 2004; Negredo et al 2004). It was also shown to 
be effective as an alternative antiviral agent during treatment 
failure or drug toxicity among treatment-experienced patients 
(Lyseng-Williamson 2005). It can be taken without regard to 
food consumption, but is absorbed 39% when taken with a 
fatty meal compared to 25% when administered before a meal 
(fasting) (Viread package insert 2005).
TDF is excreted unchanged by the kidneys; thus, renal tubular 
toxicity is an important but uncommon side effect (Ristig et al 
2002; Barrios et al 2004; James et al 2004; Murphy et al 2003; 
Schaaf et al 2003). Caution and dose adjustment is recom-
mended in renal insufﬁ  ciency/failure (Viread package insert 
2005). TDF is not metabolized by cytochrome P450 enzymes, 
so little potential for interactions with drugs metabolized by these 
enzymes exists. TDF induces little or no mitochondrial toxicity or 
dyslipidemia. Other occasional adverse reactions include nausea, 
diarrhea, vomiting, rash, and ﬂ  atulence.
Emtricitabine (FTC, Emtriva®)
Emtricitabine, FTC is a ﬂ  uorinated derivative of lamivudine 
(3TC), an analog of deoxycitidine, which is active against HIV-
1, -2 and hepatitis B virus. It has been approved by the FDA for 
use since 2003 and is currently recommended as part of an initial 
preferred HIV treatment regimen (Department of Health and 
Human Services 2006). As compared to 3TC, FTC has a longer 
half-life, higher oral bioavailability, and slightly greater potency 
in vitro, although the clinical signiﬁ  cance of this remains unclear 
(Schinazi et al 1992; Frampton et al 2005). Studies indicate that 
FTC is efﬁ  cacious in combination with other antiretrovirals in 
reducing HIV viral loads in both treatment-naïve and experienced 
patients (Molina et al 2000; Benson et al 2004; Saag et al 2004; 
Molina et al 2005). FTC can be taken without regard to food 
consumption and is completely eliminated via the kidneys, so 
dosage adjustment is required in case of renal insufﬁ  ciency (Sax 
et al 2007). Potential drug interactions and toxicity, including 
mitochondrial toxicities and dyslipidemias, are nearly absent. The 
most common side effects include headache, insomnia, diarrhea, 
nausea, vomiting, and rash (Benson et al 2004; Saag et al 2004). 
FTC may cause skin hyperpigmentation of the palms and soles 
in African and African American patients.
Tenofovir-emtricitabine
(Truvada®)
TDF-FTC is a once daily treatment composed of TDF and 
FTC to be used in combination with other antiretroviral drugs. 
The TDF-FTC co-formulation contains 300 mg of TDF and 
200 mg of FTC administered orally in one tablet that has 
Table 2 Characteristics of tenofovir and emtricitabine
Characteristics TDF  FTC  TDF-FTCa
Generic/Brand name  Tenofovir DF/ Viread  Emtricitabine/Emtriva  Truvada 
Manufacturer  Gilead Sciences  Gilead Sciences  Gilead Sciences
FDA approval date  October 2001  July 2003  August 2004a
Supplied as  300 mg tabs  200 mg caps  300 mg TDF + 200 mg FTC in one tab
Recommended dose  300 mg daily  200 mg daily  1 tab daily
Administration  Orally with or without food  Orally with or without food  Orally with or without food
Median fasted oral  25 ( not calculated – 45)  93 (83.1–106.4)  25 for TDF 92 for FTC
bioavailability (range) 
Food  effect  None None None
Toxicity  Minimal Minimal Minimal
  GI intolerance  Hyperpigmentation  GI intolerance
  Nephrotoxicity  of palm and sole  Hyperpigmentation
     Nephrotoxicity
aObtained accelerated approval in the US.Therapeutics and Clinical Risk Management 2007:3(6) 1100
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bioavailability equivalence to the single drug formulations. 
TDF and FTC have synergistic antiviral effects on HIV-1 
and HIV-2 (Louie et al 2003; Gilead Sciences 2006). The 
co-formulation is considered efﬁ  cacious therapy that can be 
used in multi-drug HIV treatment regimens (Gallant et al 
2006; Pozniak et al 2006). Recently, the US Department 
of Health and Human Services listed TDF and FTC among 
the preferred options as part of NNRTI or PI based antiviral 
combination therapy (Department of Health and Human 
Services 2006; Hammer et al 2006). TDF-FTC with the 
NNRTI efavirenz represents the most simpliﬁ  ed antiretroviral 
dosing schedule yet, consisting of two pills or a single three-
drug, ﬁ  xed-dose combination tablet (Atripla®) once a day. 
When combined with one of three currently recommended 
ritonavir-boosted PIs, the daily pill burden is a total of 4 or 
5 pills. The only other preferred NRTI ﬁ  xed-dose combina-
tion pill, zidovudine (ZDV) +3TC (Combivir®), is given 
twice a day. Other once-a-day NRTI combinations include 
ﬁ  xed-dose abacavir + lamivudine (Epzicom®) and didano-
sine with either TDF or stavudine (D4T) extended release. 
Abacavir + lamivudine, while efﬁ  cacious and well tolerated, 
has somewhat less clinical trial data supporting its use and at 
this time remains an alternate recommendation in guidelines. 
Didanosine combined with either TDF or D4T extended has 
a higher incidence of toxicity and is not recommended as 
ﬁ  rst-line therapy (Department of Health and Human Services 
2006; Hammer et al 2006).
TDF-FTC efﬁ  cacy
Gilead study 934 was the pivotal efﬁ  cacy trial for the TDF-
FTC combination (Pozniak et al 2006). This randomized, 
open-label, noninferiority trial enrolled 517 antiretroviral-
naïve, HIV-infected patients to receive either TDF + FTC 
and efavirenz or ZDV + 3TC and efavirenz. The primary 
endpoint was the proportion of patients with an HIV RNA 
level 400 copies/mL in patients without baseline non-
nucleoside resistance. Through week 96, signiﬁ  cantly more 
patients receiving TDF + FTC achieved and maintained 
an HIV RNA level 400 copies/mL (75% vs 62%). The 
TDF + FTC group also demonstrated a signiﬁ  cantly greater 
increase in CD4+ lymphocyte counts (270 vs 237 cells/mm3; 
p = 0.036).
Another clinical trial, Gilead 903, a randomized, placebo-
controlled study, compared TDF or D4T in combination with 
3TC and efavirenz in 602 treatment-naïve subjects. This study 
demonstrated equivalence in the percentage of subjects with 
HIV RNA 50 copies/mL at week 48 and through 144 with 
less lipoatrophy and more favorable lipid proﬁ  les in the TDF 
arm (Gallant et al 2004). In treatment-experienced patients, 
the TDF-FTC is commonly used as guided by drug resistance 
testing, but the relative beneﬁ  t of the combination relative to 
other NRTI/NtRTI choices is difﬁ  cult to gauge and will depend 
on many factors, including HIV genotypic or phenotypic sus-
ceptibility scores, drug interactions, and compliance. It is well 
documented that 3TC beneﬁ  ts patients with the RT M184V/I 
mutation that are incompletely suppressed virologically, pos-
sibly as a result of impairing viral ﬁ  tness or residual virologic 
activity, and likely this holds true of FTC as well.
Therapeutic use of TDF-FTC 
among special populations
No efﬁ  cacy differences have been identiﬁ  ed between male 
and female patients (Gilead Sciences 2006). Sufﬁ  cient data 
is not available to examine differences among different races 
and ethnic groups and geriatric populations. Because both 
TDF and FTC are excreted via the kidneys, modiﬁ  cation 
of TDF-FTC dosage and special caution is necessary when 
treating patients with renal impairments (Table 3) (Gilead 
Sciences 2006; Bartlett and Gallant 2005). Data on dosing in 
patients with liver impairment is limited; however, no dosing 
adjustment is recommended (Gilead Sciences 2006).
TDF and FTC are both active against HBV in vitro, in 
case series (Benhamou et al 2003), and in a small controlled 
clinical trial with HIV-HBV coinfected subjects (Peters MG 
et al 2006), but are not approved for that indication. While 
FTC has no activity against lamivudine-resistant HBV 
strains, in HIV co-infected patients with a positive HBeAg, 
the inclusion of TDF in the HIV regimen resulted in a signiﬁ  -
cant reduction of viral load, including those with lamivudine-
resistant strains (Nelson et al 2003; Dore et al 2004). TDF 
also may be active against strains of HBV resistant to the 
NtRTI adefovir and be more potent as well (Qi et al 2007; 
Lacombe et al 2007). In its most recent guideline, the Ameri-
can Association for the Study of Liver Disease (AASLD) has 
also included TDF and FTC as one of the drugs that may 
be used to treat HIV-HBV co-infected patients (Benhamou 
2006; Lok and McMahon 2007). While the efﬁ  cacy and 
safety of TDF-FTC has not been thoroughly studied in the 
treatment of HIV-HBV co-infection, several studies have 
indicated that discontinuation of TDF-FTC in HBV-infected 
patients may result in severe and acute exacerbation or ﬂ  are 
up of the hepatitis (Bessesen et al 1999; Bartlett and Gallant 
2005). Liver function tests should be monitored for at least 
several months in HIV/HBV co-infected patients who are 
suspended from treatment with TDF-FTC. Because of the 
risk of HIV resistance with two-drug therapy, if co-infected Therapeutics and Clinical Risk Management 2007:3(6) 1101
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patients require treatment, other agents such as adefovir or 
pegylated interferon should be used.
TDF-FTC is excreted in breast milk and should not be 
used while nursing (Gilead Sciences 2006). The effects of 
TDF-FTC in pregnant and nursing mothers need to be inves-
tigated further in light of its future use.
Resistance and cross-resistance
Resistance to TDF is conferred by the reverse transcriptase 
(RT) K65R and/or K70E mutations (Van Rompay et al 
2007). K65R can be selected by TDF as well as the NRTIs 
abacavir and didanosine. This mutation is relatively uncom-
mon. In antiretroviral-naïve patients, there is little baseline 
resistance to TDF. More than two of certain thymidine ana-
log mutations (TAMS – RT M41L, L210W, and T215Y/F) 
confer that resistance to TDF may be present. TDF does not 
select for TAMs. The RT M184V/I mutation is selected by 
both FTC and 3TC, though perhaps slightly less readily by 
the former, and leads to complete cross-resistance between 
the two. Interestingly, the M184V/I mutation can partially 
re-sensitize HIV that contains TAMs or the K65R muta-
tion to TDF. Using FTC or 3TC with TDF may result in a 
somewhat higher barrier to drug resistance than seen with 
TDF alone, though several triple NRTI studies using TDF 
with FTC or 3TC have demonstrated that this theoretical 
beneﬁ  t has limits.
A recent literature review indicated that resistance to 
FTC-TDF is relatively infrequent (Muñoz de Benito and 
Arribas Lopez 2006). Among the two Gilead clinical trials, 
a signiﬁ  cant difference was seen in the proportion of patients 
receiving experiencing virologic rebound on therapy that 
developed the K65R mutation, with 22% (8 of 36) of patients 
in the 903 study and no patients in the 934 study developing 
the mutation (Pozniak et al 2006). The reason for this dis-
crepancy is unclear, though follow up in 903 was longer. The 
incidence of M184V/I in the TDF arm was 39% and 14%, 
respectively, but since the incidence of virologic rebound 
was small, these do not represent large numbers.
Toxicity and adverse reactions
TDF-FTC is generally well tolerated, with few side effects 
as noted above for the individual compounds. Lactic acidosis 
and hepatomegaly with steatosis, including fatal cases, have 
been reported with most other nucleosides but have not been 
reported to occur with TDF-FTC, to our knowledge (Gilead 
Sciences 2006).
TDF and FTC are principally eliminated via the 
kidneys. Like the known nephrotoxic NtRTIs cidofovir 
and adefovir, TDF is extracted from the blood plasma 
by the human renal organic anion transporters (hOAT1 
and hOAT3), which has suggested the possibility of 
renal tubular toxicity (Uwai et al 2007). While the data 
concerning the clinical relevance on this are somewhat 
inconsistent (Mocroft et al 2007; Gayet-Ageron et al   
2007; Pozniak et al 2006; Gallant et al 2007), it appears 
that renal tubular toxicity, and occasionally Fanconi’s 
syndrome (renal tubular injury with severe hypophos-
phatemia, phosphoturia, and glycosuria), serious hyper-
kalemia (Shepp et al 2007), or acute interstitial nephritis 
may develop with TDF or TDF-FTC use. The majority of 
these cases occurred in patients with underlying systemic 
vascular insult, low glomerular filtration rates (GFR)/ 
chronic renal failure, or in patients taking nephrotoxic 
agents. Certain genetic haplotypes may be associated in 
some cases (Izzedine et al 2006), though a number of cases 
have occurred in patients without identiﬁ  able risk factors. 
Table 3 TDF, FTC and TDF-FTC dosing in renal insufﬁ  ciency and hepatic failure
Drug   Standard dose  Dose for renal insufﬁ  ciency/    Dose in hemodialysis  Hepatic failure
   failure   
TDF  300 mg qd  CrCl 30–49: 300 mg q 48 h  300 mg/wk  Standard dose
    10–29: 300 mg 2×/wk10: No
   recommendation       
FTC  200 mg qd  CrCl 30–49: 200 mg q 48 h    200 mg q96 h  No recommendation
    15–29: 200 mg q 72 h
   15: 200 mg q 96 h     
Truvada        
(TDF/FTC)  300 mg/200 mgqd  CrCl 50 standard dose qd    Not administered  Standard dose
    30–49: every 48 h     
   30 should not be     
   administered     
(Bartlett and Gallant 2005; Gilead Sciences 2006)Therapeutics and Clinical Risk Management 2007:3(6) 1102
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Because certain protease inhibitors, including lopinavir and 
atazanavir, increase the serum levels of TDF by as much as 
25%, this could be a risk factor for nephrotoxicity (Kiser 
et al 2007; Goicoechea et al 2007), and extra caution is 
advised. The drug should be used only with great caution 
in patients with reduced GFR. All HIV infected patients, 
particularly those on TDF, should have baseline and 
yearly determination of GFR using either the Cockcroft-
Gault or modification of diet in renal disease (MDRD) 
method, as well as regular assessments of serum blood 
urea nitrogen and creatinine. Consideration should be 
given to monitoring serum phosphate in those on TDF 
as well. Significant GFR or serum phosphate decline 
should prompt further evaluation and strong consideration 
for discontinuation of TDF (Ristig et al 2002; Murphy 
et al 2003; Schaaf et al 2003; Barrios et al 2004; James 
2004; Gilead Sciences 2006). It is not well-elucidated if 
TDF-induced renal tubular toxicity routinely results in 
phosphaturia or glycosuria, so the absence of these cannot 
be relied upon to exclude a role for TDF in a patient’s 
renal failure.
Subclinical renal phosphate wasting could possibly con-
tribute to a decrease in bone mineral density that was reported 
in a study conducted among treatment-naïve patients who 
were treated with TDF in Gilead 903 (Cassetti et al 2006, 
2007). A decrease in bone mineral density at the lumbar spine 
and hip, especially between weeks 24 and 48, was evident but 
was non-progressive through 288 weeks. Thus, monitoring of 
bone mineral density should be considered in patients with 
history of, or risk factors for, pathologic fractures. To the 
knowledge of the authors, no study has examined the beneﬁ  t 
of calcium and vitamin D supplementation or bisphosponates 
in this setting.
Use of TDF-FTC has been associated with fewer overall 
adverse effects than D4T-3TC or ZDV-3TC. Compared with 
ZDV , TDF is associated with a lower frequency of anemia 
(4% vs 9%, respectively; p = 0.02) (Gallant et al 2006), and 
compared with D4T, TDF is associated with fewer lipid 
abnormalities.
Both TDF and abacavir containing regimens are 
associated with less severe side effects or improvements 
in lipoatrophy, a reduction in subcutaneous fat tissue, 
particularly in the face and extremities. This condition 
may result from mitochondrial toxicity induced in par-
ticular by the thymidine analog NRTIs, ZDV and D4T. In 
Gilead 934, limb fat, measured by whole-body DEXA at 
weeks zero and 96, was significantly greater in the TDF + 
FTC + efavirenz group versus the ZDV + 3TC + efavirenz 
group (7.7 vs 5.5 kg; p  0.001) (Pozniak et al 2006). 
A similar lipoatrophy benefit with TDF was observed 
in an analysis restricted to African or African American 
study participants (Gallant et al 2007). An interesting 
twist to this story was suggested by AIDS Clinical Trial 
Group (ACTG) study 5142, which confirmed greater limb 
fat loss with D4T as compared with AZT, and ZDV as 
compared with TDF containing regimens; but in addi-
tion, NNRTI containing regimens were associated with 
greater fat loss than PI containing regimens, independent 
of which NRTi/NtRTI was used (Haubrich et al 2007). 
The mechanism for an apparent lipoatrophy-potentiating 
effect of NNRTIs on NRTIs is not understood at this time, 
but this study should prompt further investigation.
Drug interactions
It is assumed that drug interaction for TDF-FTC is the same 
when administered combined or dosed alone as TDF or FTC. 
Any medications that reduce renal function may increase con-
centration of FTC and TDF. No drug interactions with clini-
cal consequences are known for FTC. As mentioned above, 
co-administration of TDF with certain protease inhibitors, 
including atazanavir, lopinavir/ritonavir, and darunavir (TMC-
114)/ritonavir (Hoetelmans et al 2007) results in increased 
plasma levels of TDF and, in the case of atazanavir and lopi-
navir/ritonavir, reduced protease inhibitor troughs. While no 
dose adjustment is recommended when TDF is used with these 
drugs (Bartlett and Gallant 2005; DHHS 2006), in cases where 
baseline protease resistance mutations have modestly raised 
the concentration of the drug required to inhibit the virus, this 
effect of TDF could be signiﬁ  cant. Atazanvir should always be 
ritonavir boosted (atazanavir 300 mg should be boosted with 
ritonavir 100 mg) when used with TDF.
TDF should be used very cautiously with didanosine due 
to increased rates of adverse reactions including peripheral 
neuropathy and pancreatitis. This is likely a result of a drug 
interaction resulting in a 40%–50% increase in plasma 
didanosine levels (Pruvost et al 2005) and/or intracellular 
drug interactions. In addition, use of TDF with didanosine 
has also been associated with paradoxical CD4 declines or 
less than robust CD4 increases in some, but not all studies 
(Barrios 2005; Karrer et al 2005; Torti et al 2007). These 
results are reminiscent of those seen in studies combin-
ing didanosine with hydroxyurea. If co-administration of 
didanosine and TDF is necessary, didanosine dose should 
be adjusted and patients should be closely monitored for 
didanosine-related adverse reactions. The recommended 
didanosine dose for patients weighing 60 kg in this setting Therapeutics and Clinical Risk Management 2007:3(6) 1103
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is 250 mg; however, there is no adequate information for 
patients weighing below 60 kg (Gilead Sciences 2006).
Conclusion
There is sufﬁ  cient data to recommend the use of TDF-FTC 
in the treatment of HIV . It is recommended as a preferred 
and alternative treatment of choice in both treatment-naïve 
and experienced patients. In addition to its demonstrated 
efﬁ  cacy, TDF-FTC also provides signiﬁ  cant advantages in 
terms of few side effects, low long-term toxicity, once daily 
dosing, few drug interactions, useful anti-HBV activity, and a 
relatively high genetic barrier relative to other NRTIs/NtRTIs 
(Table 4). Caution must be exercised in patients with reduced 
renal function and when the drug is used with certain other 
antiretrovirals.
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